[68Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [18F]FDG and laboratory values

Authors: Constantin Lapa, Martin Schreder, Andreas Schirbel, Samuel Samnick, K. Martin Kortüm, Ken Herrmann, Saskia Kropf, H. Einsele, Andreas K. Buck, Hans‐Jürgen Wester, Stefan Knop, Katharina Lückerath - Theranostics 2016 cited by 196

Ga]Pentixafor-PET provides further evidence that CXCR4 expression frequently occurs in advanced multiple myeloma, representing a negative prognostic factor and a potential target for myeloma specific treatment. However, selecting patients for CXCR4 directed therapies and prognostic stratification seem to be more relevant clinical applications for this novel imaging modality, rather than diagnostic imaging of myeloma.